Therefore, we previously reported that positive PD-L1 expression in TICs was significantly associated with shorter RFS in “high-risk” (≥pT3a and/or pN+) UC and may be used as a prognostic biomarker of tumor recurrence following RC irrespective of adjuvant chemotherapy [28,29]. The gene discussed is CD274; the disease is neoplasm.